Skip to content

Population pharmacokinetics of tacrolimus in lung transplant patients

Population pharmacokinetics of tacrolimus in lung transplant patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031586
Enrollment
Unknown
Registered
2020-04-04
Start date
2015-01-01
Completion date
Unknown
Last updated
2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung transplantation

Interventions

Two cohorts:tacrolimus alone versus combined use

Sponsors

Wuxi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who underwent first lung transplantation and treated with oral tacrolimus; (2) Without acute rejection, dialysis treatment, severe gastrointestinal disorders, and untolerate tacrolimus-induced side effects; (3) Good adherence.

Exclusion criteria

Exclusion criteria: 1) combined organ transplantations; 2) unable to be admininstered tacrolimus orally; 3) with acute, severe chronic peptic ulcer and gastrointestinal diseases; 4) with hemodialysis or peritoneal dialysis; 5) have any form of drug abuse and mental disorders; 6) Poor adherence 7) simultaneously participate other clinical trials.

Design outcomes

Primary

MeasureTime frame
pharmacokinetic (popPK;

Contacts

Public ContactJingyu Chen

Wuxi Lung Transplant Center, Wuxi people's Hospital affiliated to Nanjing Medical University

chenjy@wuxiph.com+86 0510-85351886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026